메뉴 건너뛰기




Volumn 63, Issue 10, 2014, Pages 1020-1021

Yet another player in the cardio-oncology conundrum? Deciphering the role of FLT3

Author keywords

apoptosis; heart failure; hematopoietic cytokines; myocardial infarction; receptor tyrosine kinase

Indexed keywords

CD135 ANTIGEN; CRENOLANIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTAURTINIB; FLT3 LIGAND; LESTAURTINIB; MIDOSTAURIN; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE INHIBITOR; QUIZARTINIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

EID: 84896068439     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.058     Document Type: Editorial
Times cited : (8)

References (9)
  • 1
    • 84896102327 scopus 로고    scopus 로고
    • FLT3 activation improves post-myocardial infarction remodeling involving a cytoprotective effect on cardiomyocytes
    • O. Pfister, V. Lorenz, and A. Oikonomopoulos et al. FLT3 activation improves post-myocardial infarction remodeling involving a cytoprotective effect on cardiomyocytes J Am Coll Cardiol 63 2014 1011 1019
    • (2014) J Am Coll Cardiol , vol.63 , pp. 1011-1019
    • Pfister, O.1    Lorenz, V.2    Oikonomopoulos, A.3
  • 3
    • 0030451722 scopus 로고    scopus 로고
    • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
    • M. Nakao, S. Yokota, and T. Iwai et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 1996 1911 1918
    • (1996) Leukemia , vol.10 , pp. 1911-1918
    • Nakao, M.1    Yokota, S.2    Iwai, T.3
  • 4
    • 84883592712 scopus 로고    scopus 로고
    • Emerging paradigms in cardiomyopathies associated with cancer therapies
    • B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, and J.J. Moslehi Emerging paradigms in cardiomyopathies associated with cancer therapies Circ Res 113 2013 754 764
    • (2013) Circ Res , vol.113 , pp. 754-764
    • Ky, B.1    Vejpongsa, P.2    Yeh, E.T.3    Force, T.4    Moslehi, J.J.5
  • 5
    • 84872243145 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors: Views of selectivity, sensitivity, and clinical performance
    • A. Levitzki Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance Annu Rev Pharmacol Toxicol 53 2013 161 185
    • (2013) Annu Rev Pharmacol Toxicol , vol.53 , pp. 161-185
    • Levitzki, A.1
  • 6
    • 50949132320 scopus 로고    scopus 로고
    • Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
    • M.H. Chen, R. Kerkela, and T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
    • (2008) Circulation , vol.118 , pp. 84-95
    • Chen, M.H.1    Kerkela, R.2    Force, T.3
  • 7
    • 84872340132 scopus 로고    scopus 로고
    • Cancer genetics and the cardiotoxicity of the therapeutics
    • H. Lal, K.L. Kolaja, and T. Force Cancer genetics and the cardiotoxicity of the therapeutics J Am Coll Cardiol 61 2013 267 274
    • (2013) J Am Coll Cardiol , vol.61 , pp. 267-274
    • Lal, H.1    Kolaja, K.L.2    Force, T.3
  • 8
    • 84872031728 scopus 로고    scopus 로고
    • Neuregulin in cardiovascular development and disease
    • O. Odiete, M.F. Hill, and D.B. Sawyer Neuregulin in cardiovascular development and disease Circ Res 111 2012 1376 1385
    • (2012) Circ Res , vol.111 , pp. 1376-1385
    • Odiete, O.1    Hill, M.F.2    Sawyer, D.B.3
  • 9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.